Concepedia

Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder

Christopher R. Chapple, Steven A. Kaplan, David Mitcheson, Jiří Klečka, Jana Cummings, Ted Drogendijk, Caroline A. Dorrepaal, Nancy Martin

European Urology · 2012 · 356 citations · 8 references

DOI

Concepts

References

8

Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial

Vik Khullar, G. Amarenco, J.C. Angulo et al. · European Urology · 2012 · 425 citations

, , +14

Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive Bladder

Victor W. Νitti, Stephen M. Auerbach, Nancy Martin et al. · The Journal of Urology · 2012 · 368 citations

, , +17

A Multicenter, Double-blind, Randomized, Placebo-controlled Trial of the β3-Adrenoceptor Agonist Solabegron for Overactive Bladder

Eliot H. Ohlstein, Alexander von Keitz, Martin C. Michel · European Urology · 2012 · 113 citations

, , +14

Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial

E.S. Rovner · Yearbook of Urology · 2013 · 88 citations

, , +14

885 THE EFFICACY AND SAFETY OF MIRABEGRON IN PATIENTS WITH OVERACTIVE BLADDER SYNDROME – RESULTS FROM A NORTH-AMERICAN PHASE III TRIAL

Sender Herschorn, Sascha Auerbach, Mark Ayers et al. · European Urology Supplements · 2011 · 46 citations

, , +6